<DOC>
	<DOCNO>NCT01657682</DOCNO>
	<brief_summary>This pilot Phase II study design evaluate efficacy tolerability crenolanib two cohort AML patient FLT3 activation mutation ( patient whose leukemia recur prior chemotherapy include FLT3 TKI patient whose leukemia progress prior therapy FLT3 TKI ) .</brief_summary>
	<brief_title>A Phase II Study Crenolanib Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations</brief_title>
	<detailed_description>This Phase II open label study crenolanib besylate . This study enroll subject relapse acute myeloid leukemia ( AML ) FLT3 activate mutation . Two cohort patient enrol : whose AML recur prior chemotherapy without FLT3 TKI , whose AML progress prior therapy FLT3 TKIs . Subjects take Crenolanib besylate 100 mg TID disease progression , death , unacceptable toxicity . Concurrent hydroxyurea permit first 28 day study therapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<criteria>Confirmed primary AML relapse refractory prior therapy , AML secondary antecedent chemotherapy radiation therapy , AML due prior myelodysplastic syndrome ( MDS ) / myeloproliferative neoplasm ( MPN ) define WHO criteria presence either FLT3 ITD and/or FLT3 activate mutation Patients secondary AML fail two ( 2 ) prior regimens Patients antecedent MDS/MPN , define WHO criterion , without prior therapy AML , regardless number therapy MDS/ MPN Patients primary AML receive two ( 2 ) prior cytotoxic contain salvage regimen . Reinduction regimen stem cell transplant consider separate salvage regimen . Change drug consider salvage regimen . Unlimited FLT3 TKI therapy ( even combination cytotoxics/hypomethylating agent ) allow patient enrol cohort B Patients must test positive FLT3ITD /or FLT3 activate mutation within 30 day screen period Males females age ≥18 year ECOG PS 02 Adequate liver function , define bilirubin ≤1.5x ULN , ALT ≤3.0x ULN , AST ≤3.0x ULN Adequate renal function , define serum creatinine ≤1.5x ULN Recovery nonhematological toxicity prior therapy ( include HSCT ) grade 1 ( except alopecia ) Subjects receive antileukemic therapy ( except hydroxyurea ) prior first dose crenolanib follow : 14 day classical cytotoxic agent five time t1/2 ( halflife ) FLT3 inhibitor antineoplastic agent neither cytotoxic FLT3 inhibitor ( e.g . hypomethylating agent MEK inhibitor ) Negative pregnancy test WOCBP Able willing provide write informed consent . Absence FLT3 activate mutation &lt; 5 % blast blood marrow screen Concurrent chemotherapy , targeted anticancer agent , hydroxyurea Patient concurrent severe and/or uncontrolled medical condition opinion investigator may impair participation study evaluation safety and/or efficacy HIV infection active hepatitis B ( define hepatitis B surface antigen positive ) C ( define hepatitis C antibody positive ) Known clinically active central nervous system ( CNS ) leukemia Patients less 30 day post HSCT Subjects clinically significant graft versus host disease require treatment /or &gt; grade 2 persistent non hematological toxicity relate transplant Prior crenolanib treatment nonleukemic indication Major surgical procedure within 14 day Day 1 administration crenolanib . Unwillingness inability comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>FLT3</keyword>
	<keyword>Crenolanib</keyword>
	<keyword>Acute</keyword>
	<keyword>Myeloid</keyword>
	<keyword>AML</keyword>
</DOC>